Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
|Podcasts|April 1, 2017
Podcast: This Week in Managed Care - New Breast Cancer Guidelines, and Other News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Advertisement
Every week, The American Journal of Managed Care® recaps the
This week, the top managed care news included new radiology guidelines for early-stage breast cancer; 4 continuing healthcare challenges for President Donald Trump; and Medicare coverage for Dexcom's continuous glucose monitor.
Listen below or through one of these podcast services:
iTunes:
TuneIn:
Stitcher:
Advertisement
Related to this article
Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.
KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.
The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
4
Youths With Depression Face Higher Odds of Prescription Drug Misuse
5